Septerna, Inc. Common Stock (SEPN)
Septerna, Inc. is a biotechnology company focused on developing innovative therapies targeting G protein-coupled receptors (GPCRs) to address unmet medical needs. The company leverages advanced research and proprietary technology platforms to discover and advance novel drugs in areas such as neuroscience, immunology, and metabolic diseases.
Company News
Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.
Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (NASDAQ:SEPN) after the company announced the discontinuation of a clinical trial for its hypoparathyroidism treatment due to unexpected severe cases of elevated unconjugated bilirubin.